PTU - Polskie Towarzystwo Urologiczne
home page
current numbers
archival numbers
list of articles:
list przewodni/covering letter
editor
Scientific Committee
publisher
subscription
advertising
important links

Urological literature review: November 2005 - October 2006. Part I
Article published in Urologia Polska 2007/60/1.

authors

Andrzej Borkowski, Tomasz Borkowski
Klinika Urologii Akademii Medycznej w Warszawie

references

  1. 1. Busby JE, Kamat AM: Chemoprevention for bladder cancer. J Urol 2006, 176, 1914-1920.
  2. 2. Leibovici D, Grossman HB, Dinney CP i et al: Polimorphisms in inflamation genes and bladder kancer, from initiation to recurrence, progression and survival. J Clin Oncol 2005, 23, 5746-56.
  3. 3. O?Donnell M: Entrez into the immunogenetics of superficial bladder cancer response to Bacilllus Calmette-Guerin. J Urol 2006, 175, 1197-98.
  4. 4. Colombel M, Saint F, Chopin D et al: The effect of ofloxacin on Bacillus Calmette-Guerin induced toxicity in patients with superficial bladder cancer, results of a randomised, prospective, double-blind, placebo controlled, multicenter study. J Urol 2006, 176, 935-939.
  5. 5. Neuzillet Y, Cabaniols L, Karam G et al: Etude des tumeurs urotheliales de vessie chez les transplantes renaux. Prog Urol 2006, 16, 343-46.
  6. 6. Kamat AM, Nelkin GM: Atorvastatin, a ppotential chemopreventive agent in bladder cancer. Urology 2005, 66, 1209-1212.
  7. 7. Gontero P, Marini L, Frea B: Intrevesical gemcitabine for superficial bladder cancer, rationale for a new treatment option. BJU Int 2005, 96, 970-976.
  8. 8. Van der Heijden A, Moonen PMJ, Cornel EB et al: Phase II marker lesion study with intravesical instillation of Apaziquine for superficial bladder cancer, toxicity and marker response. J Urol 2006, 176, 1349-1353.
  9. 9. Weiss Ch, Wolze C, Egehausen DG et al: Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer, an alternative to intravesical therapy or early cystectomy. J Clin Oncol 2006, 24, 2318-2324.
  10. 10. Sylvester RJ, Van der Meijden APM, Oosterlinck W et al: Predicting recurrence and progression in individual patients with stage TaT1 bladder cancer using EORTC risk tables, a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006, 49, 466-477.
  11. 11. Kassouf W, Swanson D, Kamat AM et al: Partial cystectomy for muszle invasive urothelial carcinoma of the bladder, a contemporary review of the M. D. Anderson Cancer Center experience. J Urol 2006, 175, 2058-2062.
  12. 12. Palapattu GS, Shariat SF, Karakiewicz PI et al: Cancer specific outcomes In patients with PT0 disease following radical cystectomy. J Urol 2006, 175, 1645-1649.
  13. 13. Manoharan M, Reyes MA, Kava BR et al: Is adjuvant chemotherapy for bladder cancer safer in patients with an ileal conduit than a neobladder. BJU Int 2005, 96, 1286-1289.
  14. 14. Letourneux H, Lindner V, Lang H et al: Reproductilibite du grade nucleaire de Fuhrman. Advantages d?un regroupement en deux grades. Prog Urol 2006, 16, 281-285.
  15. 15. Chwala SM, Crispen PL, Hanlon AL et al: The natural history of observed enhacing renal masses, meta-analysis and review of the world literature. J Urol 2006, 175, 425-31.
  16. 16. Vasudevan A, Davies RJ, Shannon BA et al: Incidental renal tumors, the fequency of benign lesions and the role of preoperative core biopsy. BJU Int 2006, 97, 946-949.
  17. 17. Mullerad M, Kastin A, Adusumilli PS et al: Comparison of nephron-sparing surgery in centtral versus peripheral renal tumors. Urology 2005, 65, 467-472.
  18. 18. Frank I, Colombo JR Jr, Rubinstein M et al: Laparoscopic partial nephrectomy for centrally located renal tumors. J Urol 2006, 175, 849-852.
  19. 19. Goel MC, Matin FS, Derweesh I et al: Partial nephrectomy for renal urothelial tumors, clinical update. Urology 2006, 67, 490-95.
  20. 20. Langner C, Hutterer G, Chromecki Th et al: Tumor necrosis as prognostic indicator in transitional cell carcinoma of the upper urinary tract. J Urol 2006, 176, 910-914.
  21. 21. Gill IS, Remer EM, Hasan WA et al: Renal cryoablation, outcome at 3 years. J Urol 2005, 173, 1903-1907.
  22. 22. Ewalt DH, Diamond M, Rees Ch et al: Long-term outcome of transcatheter embolization of renal angiolipomas due to tuberous sclerosis complex. J Urol 2005, 174, 1764-1766.
  23. 23. Vogelzang NJ: Treatment options in metastatic renal carcinoma, an embarassement of riches. J Clin Oncol 2006, 24, 1-3.
  24. 24. Patard J-J, Rioux-Leclerq N, Fergelot P: Understanding the importance of smart drugs in renal cell carcinoma. Eur Urol 2006, 49, 633-643.
  25. 25. Sternberg C: Effects of new advances in drug therapy for kidney cancer. AUA News November 2005, 24-27.
  26. 26. Raj GV, Bochner BH, Serio AM et al: Natural history of positive urinary cytology after radical cystectomy. J Urol 2006, 176, 2000-2005.
  27. 27. Tsukamoto T, Yonese J, Qhkubo Y et al: Phase I/II study of a combined Gemcitabine, Etoposide, and Cisplatin chemotherapy regimen for metastatic urothelial carcinoma. Cancer 2006, 106, 2363-2368.
  28. 28. Lin Ch-Ch, Hsu Ch-H, Huang Ch-Y et al: Weekly Cisplatin plus infusional high-dose 5-Fluorouracil and Leucovorin (P-HDFL) for metastatic urothelial carcinoma. Cancer 2006, 106, 1269-1275.
  29. 29. Steingart R: Mechanisms of late cardiovascular toxicity from cancer chemotherapy. J Clin Oncol 2005, 23, 9051-9052.
  30. 30. Trojan L, Bode Ch, Weiss CH et al: IGF-II levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging. Eur Urol 2006, 49, 286-292.
  31. 31. MacLennan GT, Eisenberg R, Fleshman RL et al: The influence of chronic inflammation in prostatic carcinogenesis, a 5-year followup study. J Urol 2006, 176, 1012-1016.
  32. 32. Sarma AV, McLaughlin JC, Wallner LP et al: Sexual behavior, sexually transmitted diseases and prostatitis, the risk of prostate cancer in back men. J Urol 2006, 176, 1108-1113.
  33. 33. Nishiyama T, Ikarashi T, Hasimoto Y et al: Association between the dihydrotestosterone level in the prostate and prostate cancer aggressiveness using the Gleason score. J Urol 2006, 176, 1387-1391.
  34. 34. Freedland SJ, Partin AW: Prostate-specific antigen, update 2006. Urology 2006, 67, 458-460.
  35. 35. Stephenson AJ, Kattan MW: Nomograms for prostate cancer. BJU Int 2006, 98, 39-46.
  36. 36. Gwede CK, Pow-Sang J, Seigne J et al: Treatment decision-making strategies and influences in patients with localized prostate cancer. Cancer 2005, 104, 1381-1390.
  37. 37. Hattab EM, Koch MO, Eble JN et al: Tertiary Gleason pattern 5 is a powerful predictor of biochemical relapse in patients with Gleason score 7 prostatic adenocarcinoma. J Urol 2006, 175, 1695-1699.
  38. 38. Donohue JF, Bianco FJ, Kuroiwa K et al: Poorly differentiated prostate cancer treated with radical prostatectomy, long-term outcome and incidence of pathological downgrading. J Urol 2006, 176, 991-995.
  39. 39. Cooperberg MR Moul JW, Carroll PR: The changing face of the prostate cancer. J Clin Oncol 2005, 23, 8146-8151.
  40. 40. Klotz L: Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancer. Eur Urol 2005, 47, 16-21.
  41. 41. Welch GH, Scwartz LM, Woloshin S: Prostate-specific antigen levels in the United States, implications of various definitions for abnormal. J Natl Cancer Inst 2005, 97, 1132-1137.
  42. 42. Albertsen PC, Hanley JA, Fine J: 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005, 293, 2095-2101.
  43. 43. Andren O, Fall K, Franzen L et al: How well does the Gleason score predict cancer death? A 20-year followup of a population based cohort in Sweeden. J Urol 2006, 175, 1337-1340.
  44. 44. Bill-Axelson A, Holmberg L Ruutu M et al: Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005, 352, 1977-1985.
  45. 45. Kulkarni GS, Rami A-A, Lockwood G et al: Evidence for a biopsy derived grade artefakt among larger prostate glands. J Urol 2006, 175, 505-509.
  46. 46. Chun FK-H, Steuber T, Erbersdobler A et al: Developement and internal validation of a nomogram predicting the probability of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathology. Eur Urol 2006, 49, 820-826.
  47. 47. Perrin P: PSA velocity and prostate cancer detection, the absence of evidence is not the evidence of absence. Eur Urol 2006, 49, 418-419.
  48. 48. Klotz L, Nam R: Active surveillance with selective delayed intervention for favourable risk prostate cancer, clinical experiebce and a 'number needed to treat' analysis. Eur Suppl 5, 2006, 479-496.
  49. 49. Klotz L, Loblaw A, Nam R: Updated follow-up of active surveillance with selected delayed intervention for localised prostate cancer. Eur Urol suppl 5, 2006, abstr. 1187.
  50. 50. Roemeling S, Robol MJ, Postma R et al: Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance. Eur Urol 2006, 50, 475-482.
  51. 51. Konski A, Eisenberg D, Horwitz E: Does age matter in the selection of treatment for men with early-stage prostate cancer. Cancer 2006, 106, 2598-602.
  52. 52. Zelefsky MJ, Chan H, Hunt M et al: Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localised prostate cancer. J Urol 2006, 176, 1415-1419.
  53. 53. Johnstone PAS, Ward KC, Goodman M et al: Radical prostatectomy for clinical T4 prostate cancer. Cancer 2006, 106, 2603-2609.
  54. 54. Swanson G, Thompson I, Basler J et al: Metastatic prostate cancer-does treatment of the primary tumor matter? J Urol 2006, 176, 1292-1298.
  55. 55. Pazona JF, Han M, Hawkins SA et al: Salvage radiation therapy for prostatic specific antigen progression following radical prostatectomy, 10-year outcome estimates. J Urol 2005, 174, 1282-1286.
  56. 56. Bolla M, van Poppel H, Collette L et al: Postoperative radiotherapy after radical prostatectomy, a randomised controlled trial (EORTC trial 22911). Lancet 2005, 366, 572-578.
  57. 57. Teh BS, Bastasch MD, Mai W-Y et al: Long-term benefis of elective radiotherapy after prostatectomy for patients with positive surgical margines. J Urol 2006, 175, 2097-2102.
  58. 58. D?Amico AV, Chen M-H, Roehl A et al: Identifying patients at risk for significant versus insignificant postoperative prostate-specific antigen failure. J Clin Oncol 2005, 23, 4975-4979.
  59. 59. Wong WW, Buskirk SJ, Schild SE et al: Combined prostate brachyterapy and short-term androgen deprivation therapy as salvage therapy for locally recurrent prostate cancer after external beam irradiation. J Urol 2006, 176, 2020-2024.
  60. 60. Dobs A, Darkers MJM: Incidence and management of gynecomastia in men treated for prostate cancer. J Urol 2005, 174, 1737-1742.
  61. 61. Studer UE, Whelan P, Albrecht W et al: Immediate or deferred androgen deprivation for patients with prostate kancer not suitable for local treatment with curative Entent, European Organisation for Research and Treatment of Cancer (EORTC) tral 30891. J Clin Oncol 2006, 24, 1868-1876.
  62. 62. Abrahamsson P-A, Anderson J, Boccon-Gibod L et al: Risks and benefits of hormonal manipulation as monotherapy for adjuvant treatment in localised prostate cancer. Eur Urol 2005, 48, 900-905.
  63. 63. Walsh PC: Accelerated deaths using Bicalutamide 150 mg in patients with localized prostate cancer. AUA News 2005, 10 (zeszyt 1), 1.
  64. 64. Pintus JH, Trachtenberg J, Klotz L: Cardiovascular effects of androgen depletion and replacement therapy. Urology 2006, 67, 1126-1132.
  65. 65. Stewart AJ, Scher HI, Chen M-H et al: Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol 2005, 23, 6556-6560.
  66. 66. Semeniuk RC, Venner PM, North S: Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer. Urology 2006, 68, 565-69.
  67. 67. Michels J, Montemurro T, Murray N et al: First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer. Cancer 2006, 106, 1041-1046.
  68. 68. Sternberg CN: Satraplatin in treatment of hormone-refrectory prostate cancer. BJU Int 2005, 96, 990-994.
  69. 69. Moyad MA, Merrick GS, Butler WM et al: Statins, especially Atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer. Urology 2005, 66, 1150-1154.
  70. 70. Karlsson CT, Malmer B, Wiklund F et al: Breast cancer as a second primary in patients with prostate cancer-estrogen treatment or association with family history of cancer. J Urol 2006, 176, 538-43.

correspondence

Andrzej Borkowski
Klinika Urologii AM
ul. Lindleya 4
02-005 Warszawa
tel. (022) 502 17 23
urolwa@warman.com.pl